A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Pfizer
- Study ID
- NCT07845500
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Obesity
- Overweight
- Overweight and/or Obesity
- Treatment Of Obesity
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Semaglutide — DRUGParticipants will receive Semaglutide administered subcutaneously.
- Berobenatide — DRUGParticipants will receive berobenatide solution for injection as subcutaneous injection.
- Tirzepatide — DRUGParticipants will receive Tirzepatide administered subcutaneously.
Study Details
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes. Participants will be in the study for about 11 months.
Key Dates
- First listed
- Sep 29, 2026
- Start date
- Sep 30, 2026
- Status verified
- Oct 2026
- Primary completion
- Feb 16, 2028
- Completion
- Feb 16, 2028
Study Design
- Enrollment
- 660 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Active ComparatorParticipants will receive Semaglutide or Tirzepatide by Subcutaneous Injection.
- Experimental: ExperimentalParticipants will receive Berobenatide by Subcutaneous Injection.
Primary Outcome Measure
Percent change from baseline in body weight [ Time Frame: Baseline, Week 32 ]
Central Contacts
- Pfizer CT.gov Call Center1-800-718-1021
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | - |
| Velocity Clinical Research - Los Angeles | Los Angeles | California | 90017 | - |
| Southern California Clinical Research | Santa Ana | California | 92701 | - |
| Diablo Clinical Research, LLC dba Flourish Research | Walnut Creek | California | 94598 | - |
| Jacksonville Center for Clinical Research | Jacksonville | Florida | 32216 | - |
| Suncoast Clinical Research | New Port Richey | Florida | 34652 | - |
| Oviedo Medical Research | Oviedo | Florida | 32765 | - |
| Monroe Biomedical Research | Louisville | Kentucky | 40213 | - |
| Aa Mrc Llc | Flint | Michigan | 48504 | - |
| SKY Integrative Medical Center/SKYCRNG | Ridgeland | Mississippi | 39157 | - |
| Clinical Research Professionals | Chesterfield | Missouri | 63005 | - |
| Mercury Street Medical Group, PLLC | Butte | Montana | 59701 | - |
| Monroe Biomedical Research | Monroe | North Carolina | 28112 | - |
| Accellacare - Wilmington | Wilmington | North Carolina | 28401 | - |
| Velocity Clinical Research, Mt. Auburn | Cincinnati | Ohio | 45219 | - |
| Tribe Clinical Research, LLC | Greenville | South Carolina | 29607 | - |
Find similar trials in Birmingham, AL
By condition
By specialty
By research site
University of Alabama at Birmingham· Birmingham, ALVelocity Clinical Research - Los Angeles· Los Angeles, CASouthern California Clinical Research· Santa Ana, CADiablo Clinical Research, LLC dba Flourish Research· Walnut Creek, CAJacksonville Center for Clinical Research· Jacksonville, FLSuncoast Clinical Research· New Port Richey, FL
Related Studies
- Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight MaintenanceRecruiting · University of Michigan · Ann Arbor, Michigan
- Bariatric Embolization of Arteries for the Treatment of Nonalcoholic SteatohepatitisNot Yet Recruiting · Keith Pereira, MD: · St Louis, Missouri
- Inflammation, Diabetes, Ethnicity and Obesity CohortRecruiting · University of California, San Francisco · San Francisco, California
- Supplementing L-citrulline to Overweight Late Asthma oNset PhenotypesPHASE2 · Recruiting · University of Colorado, Denver · Durham, North Carolina